Kiadis Sciences

Kiadis Pharma is a clinical-stage biopharmaceutical company specializing in the development of innovative cell-based immunotherapies for patients with life-threatening diseases. The company's proprietary K-NK cell platform focuses on harnessing the natural power of Natural Killer (NK) cells to treat cancer, particularly blood cancers like acute myeloid leukemia. Following its acquisition by Sanofi in 2021, Kiadis operates as a center of excellence for NK cell research and development within Sanofi's oncology pipeline. Its pipeline includes off-the-shelf NK cell products designed to be used in combination with other therapies or as standalone treatments. The company's technology aims to provide rapid, universal access to cell therapies without the need for complex patient-specific manufacturing.